Patient P-01407
Therapy response
Stable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 No meaningful change — Dietary Support Protocol NP-02
- Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 52 GI-04 recommended — GI Support Protocol GI-04
- Day 53 Patient declined — Not now
What changed?
Trajectory began diverging from predicted response on Day 48.
Primary contributors, last 14 days
- Toxicity+10
- GI instability+9
- Nutritional resilience-8
- Treatment adherence-4
- Inflammatory activity+2
What helped?
- Dietary Support Protocol NP-02Day 31Result: no meaningful change
- GI Support Protocol GI-04Day 52Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Autonomic recovery ↓65
- WearableResting HR 74 bpm
- Wearable395 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 77 and rising
- WearableSleep 5.2 h, below personal baseline
- Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 67
- WearableHRV 20 ms, trending down
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 57
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 30/100
- Daily logFibre intake low in recent food logs
DNA
Fictional pharmacogenomic panel
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.4 · butyrate capacity 30/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 25 ms
- Sleep
- 5.5 h
- Steps
- 962
- Resting HR
- 75 bpm
Daily log: GI score 77, nutritional resilience 29, adherence 41.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01492 | 47% | S15 | ME-01 | improved | 44 |
| P-01605 | 46% | S14 | ME-01 | improved | 41 |
| P-01720 | 45% | S14 | NP-02 | improved | 47 |
| P-01751 | 45% | S14 | ME-01 | improved | 48 |
| P-01615 | 44% | S14 | ME-01 | improved | 48 |
| P-01736 | 42% | S03 | ME-01 | improved | 46 |
| P-01739 | 42% | S14 | ME-01 | improved | 44 |
| P-01854 | 42% | S14 | ME-01 | improved | 46 |
| P-01897 | 42% | S14 | ME-01 | improved | 43 |
| P-01311 | 41% | S14 | ME-01 | improved | 49 |
| P-01656 | 41% | S14 | ME-01 | improved | 41 |
| P-01564 | 40% | S14 | ME-01 | improved | 39 |